This invention discloses urinary
metabolic biomarkers for
hyperuricemia and their applications, relating to the field of
metabolomics technology. It aims to overcome the shortcomings of traditional
serum uric acid detection, such as susceptibility to interference, insufficient early warning capabilities, and a lack of sensitive, specific, and non-invasive biomarkers. The urinary metabolic biomarker is at least one of L-
kynurenine, indole, and
betaine, which can be used to prepare reagents or kits. The assessment
system includes a sample analysis unit and a
risk assessment model. This invention enables non-invasive and convenient detection of
hyperuricemia, accurately captures early metabolic abnormalities, provides reliable
risk stratification, and supports clinical auxiliary diagnosis and
pathogenesis research.